Clinical Trials for Use of Melatonin to Fight against COVID-19 Are Urgently Needed

The recent pandemic of COVID-19 has already infected millions of individuals and has resulted in the death of hundreds of thousands worldwide. Based on clinical features, pathology, and the pathogenesis of respiratory disorders induced by this and other highly homogenous coronaviruses, the evidence...

Full description

Bibliographic Details
Main Authors: Konrad Kleszczyński, Andrzej T. Slominski, Kerstin Steinbrink, Russel J. Reiter
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Nutrients
Subjects:
Online Access:https://www.mdpi.com/2072-6643/12/9/2561
_version_ 1797555854001569792
author Konrad Kleszczyński
Andrzej T. Slominski
Kerstin Steinbrink
Russel J. Reiter
author_facet Konrad Kleszczyński
Andrzej T. Slominski
Kerstin Steinbrink
Russel J. Reiter
author_sort Konrad Kleszczyński
collection DOAJ
description The recent pandemic of COVID-19 has already infected millions of individuals and has resulted in the death of hundreds of thousands worldwide. Based on clinical features, pathology, and the pathogenesis of respiratory disorders induced by this and other highly homogenous coronaviruses, the evidence suggests that excessive inflammation, oxidation, and an exaggerated immune response contribute to COVID-19 pathology; these are caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This leads to a cytokine storm and subsequent progression triggering acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), and often death. We and others have reported melatonin to be an anti-inflammatory and anti-oxidative molecule with a high safety profile. It is effective in critical care patients by reducing their vascular permeability and anxiety, inducing sedation, and improving their quality of sleep. As melatonin shows no harmful adverse effects in humans, it is imperative to introduce this indoleamine into clinical trials where it might be beneficial for better clinical outcomes as an adjuvant treatment of COVID-19-infected patients. Herein, we strongly encourage health care professionals to test the potential of melatonin for targeting the COVID-19 pandemic. This is urgent, since there is no reliable treatment for this devastating disease.
first_indexed 2024-03-10T16:54:36Z
format Article
id doaj.art-10273af1d46f4f80b6ff5b58b1a271ff
institution Directory Open Access Journal
issn 2072-6643
language English
last_indexed 2024-03-10T16:54:36Z
publishDate 2020-08-01
publisher MDPI AG
record_format Article
series Nutrients
spelling doaj.art-10273af1d46f4f80b6ff5b58b1a271ff2023-11-20T11:10:57ZengMDPI AGNutrients2072-66432020-08-01129256110.3390/nu12092561Clinical Trials for Use of Melatonin to Fight against COVID-19 Are Urgently NeededKonrad Kleszczyński0Andrzej T. Slominski1Kerstin Steinbrink2Russel J. Reiter3Department of Dermatology, University of Münster, Von-Esmarch-Str. 58, 48149 Münster, GermanyDepartment of Dermatology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294, USADepartment of Dermatology, University of Münster, Von-Esmarch-Str. 58, 48149 Münster, GermanyDepartment of Cellular and Structural Biology, UT Health, San Antonio, TX 78229, USAThe recent pandemic of COVID-19 has already infected millions of individuals and has resulted in the death of hundreds of thousands worldwide. Based on clinical features, pathology, and the pathogenesis of respiratory disorders induced by this and other highly homogenous coronaviruses, the evidence suggests that excessive inflammation, oxidation, and an exaggerated immune response contribute to COVID-19 pathology; these are caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This leads to a cytokine storm and subsequent progression triggering acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), and often death. We and others have reported melatonin to be an anti-inflammatory and anti-oxidative molecule with a high safety profile. It is effective in critical care patients by reducing their vascular permeability and anxiety, inducing sedation, and improving their quality of sleep. As melatonin shows no harmful adverse effects in humans, it is imperative to introduce this indoleamine into clinical trials where it might be beneficial for better clinical outcomes as an adjuvant treatment of COVID-19-infected patients. Herein, we strongly encourage health care professionals to test the potential of melatonin for targeting the COVID-19 pandemic. This is urgent, since there is no reliable treatment for this devastating disease.https://www.mdpi.com/2072-6643/12/9/2561melatoninCOVID-19inflammationimmune responseclinical trials
spellingShingle Konrad Kleszczyński
Andrzej T. Slominski
Kerstin Steinbrink
Russel J. Reiter
Clinical Trials for Use of Melatonin to Fight against COVID-19 Are Urgently Needed
Nutrients
melatonin
COVID-19
inflammation
immune response
clinical trials
title Clinical Trials for Use of Melatonin to Fight against COVID-19 Are Urgently Needed
title_full Clinical Trials for Use of Melatonin to Fight against COVID-19 Are Urgently Needed
title_fullStr Clinical Trials for Use of Melatonin to Fight against COVID-19 Are Urgently Needed
title_full_unstemmed Clinical Trials for Use of Melatonin to Fight against COVID-19 Are Urgently Needed
title_short Clinical Trials for Use of Melatonin to Fight against COVID-19 Are Urgently Needed
title_sort clinical trials for use of melatonin to fight against covid 19 are urgently needed
topic melatonin
COVID-19
inflammation
immune response
clinical trials
url https://www.mdpi.com/2072-6643/12/9/2561
work_keys_str_mv AT konradkleszczynski clinicaltrialsforuseofmelatonintofightagainstcovid19areurgentlyneeded
AT andrzejtslominski clinicaltrialsforuseofmelatonintofightagainstcovid19areurgentlyneeded
AT kerstinsteinbrink clinicaltrialsforuseofmelatonintofightagainstcovid19areurgentlyneeded
AT russeljreiter clinicaltrialsforuseofmelatonintofightagainstcovid19areurgentlyneeded